Cancer Family
Head and Neck Neoplasm
CI-CAN-00000021Explore in graph →
Non-malignant1,572 active trials17 approved drugs142 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000021Explore in graph →
Clinical trials
6,373 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05076760 | MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors | recruiting | Phase 1 | 40 | Memgen, Inc.INDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06789172 | A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors(INVOKE) | recruiting | Phase 1 | 146 | EpkinINDUSTRY | 3 | Jun 11, 2026 | clinicaltrials |
| NCT07517198 | Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors | recruiting | Phase 1 | 40 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT04340258 | Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC | active not recruiting | Phase 1 / Phase 2 | 50 | University of CincinnatiOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07630363 | PTC-Guided Atorvastatin Plus Axitinib and Toripalimab in Advanced RCC | not yet recruiting | Phase 1 / Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT03132922 | MAGE-A4ᶜ¹º³²T for Multi-Tumor | active not recruiting | Phase 1 | 71 | USWM CT, LLCINDUSTRY | 2 | Jun 4, 2026 | clinicaltrials |
| NCT05784012 | Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma(RADIAN) | active not recruiting | Phase 1 / Phase 2 | 34 | Grupo Español de Tratamiento de Tumores de Cabeza y CuelloOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT05039801 | IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors | recruiting | Phase 1 | 54 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05783622 | Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies | active not recruiting | Phase 1 | 130 | Janux TherapeuticsINDUSTRY | 1 | Jun 1, 2026 | clinicaltrials |
| NCT04514484 | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | active not recruiting | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 1 | May 28, 2026 | clinicaltrials |
| NCT05910827 | A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers | recruiting | Phase 1 / Phase 2 | 398 | Hummingbird BioscienceINDUSTRY | 5 | May 27, 2026 | clinicaltrials |
| NCT06648096 | Afatinib in Patients With Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)(AFAN) | recruiting | Phase 1 / Phase 2 | 25 | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauOTHER | 2 | May 27, 2026 | clinicaltrials |
| NCT04589624 | An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck Undergoing Radiation Therapy and/or Systemic Therapy | recruiting | Phase 1 | 42 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06238479 | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors(EXCEED) | active not recruiting | Phase 1 | 490 | Eli Lilly and CompanyINDUSTRY | 7 | May 22, 2026 | clinicaltrials |
| NCT07601204 | Treatment of Recurrent/Metastatic Head and Neck Cancer | not yet recruiting | Phase 1 / Phase 2 | 128 | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.INDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT04969835 | A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours | recruiting | Phase 1 | 158 | Avacta Life Sciences LtdINDUSTRY | 2 | May 15, 2026 | clinicaltrials |
| NCT01947023 | Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery | active not recruiting | Phase 1 | 23 | National Cancer Institute (NCI)NIH | 1 | May 14, 2026 | clinicaltrials |
| NCT06673329 | Brodalumab in the Treatment of Immune-Related Adverse Events | recruiting | Phase 1 | 11 | Brian Henick, MDOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07583316 | A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors | not yet recruiting | Phase 1 | 192 | Corregene Biotechnology Co., LtdINDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT07583914 | Safety, Tolerability, and Preliminary Antitumor Activity of Non-Cationic Peptide-CD47 siRNA in Advanced Solid Tumors | not yet recruiting | Phase 1 | 9 | West China HospitalOTHER | 0 | May 13, 2026 | clinicaltrials |
| NCT07584499 | Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors(MRG003) | recruiting | Phase 1 | 51 | Sun Yat-sen UniversityOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06747390 | Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery(856397) | recruiting | Phase 1 | 30 | Ryan CareyOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT06802835 | EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma | recruiting | Phase 1 / Phase 2 | 148 | Sun Yat-sen UniversityOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT07217028 | Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma | recruiting | Phase 1 | 25 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05747625 | (89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma | recruiting | Phase 1 | 60 | Eben RosenthalOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06380816 | A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer | recruiting | Phase 1 / Phase 2 | 167 | Cancer Research UKOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07279116 | ABY-029 Head & Neck Trial | not yet recruiting | Phase 1 | 24 | Dartmouth-Hitchcock Medical CenterOTHER | 0 | May 7, 2026 | clinicaltrials |
| NCT04403620 | HYPORT: A Phase I/II Study of Hypofractionated Post-operative Radiation Therapy for Head and Neck Cancer | active not recruiting | Phase 1 / Phase 2 | 59 | University of Texas Southwestern Medical CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06239194 | Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 285 | ModeX Therapeutics, An OPKO Health CompanyINDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT07040072 | Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCC(LONG'E) | recruiting | Phase 1 | 10 | Beijing Tongren HospitalOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT02088645 | 177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer.(Lumed) | active not recruiting | Phase 1 | 24 | University Hospital, Basel, SwitzerlandOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT03465618 | A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors | active not recruiting | Phase 1 | 17 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT05308732 | Safety and Tolerability of the Use of Copaiba in Patients With Oral Cancer Submitted to Radiotherapy | active not recruiting | Phase 1 | 20 | Instituto Nacional de Cancer, BrazilOTHER_GOV | 1 | May 1, 2026 | clinicaltrials |
| NCT02495896 | Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 61 | University of Southern CaliforniaOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT02812524 | Ipilimumab for Head and Neck Cancer Patients | active not recruiting | Phase 1 | 18 | Providence Health & ServicesOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT05108870 | TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers | active not recruiting | Phase 1 / Phase 2 | 35 | University of ChicagoOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT00669734 | Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery | active not recruiting | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Apr 23, 2026 | clinicaltrials |
| NCT03157128 | A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)(LIBRETTO-001) | active not recruiting | Phase 1 / Phase 2 | 857 | Eli Lilly and CompanyINDUSTRY | 16 | Apr 16, 2026 | clinicaltrials |
| NCT03114462 | Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer | recruiting | Phase 1 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07455032 | Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas | recruiting | Phase 1 | 22 | Fox Chase Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05232851 | A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer | active not recruiting | Phase 1 / Phase 2 | 20 | Mayo ClinicOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT06097468 | Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC) | recruiting | Phase 1 / Phase 2 | 40 | University of California, San FranciscoOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03975231 | Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer | recruiting | Phase 1 | 6 | City of Hope Medical CenterOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT06444815 | A Study of VET3-TGI in Patients With Solid Tumors(STEALTH-001) | recruiting | Phase 1 | 60 | KaliVir ImmunotherapeuticsINDUSTRY | 1 | Apr 7, 2026 | clinicaltrials |
| NCT06517888 | Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma | recruiting | Phase 1 / Phase 2 | 27 | Akouos, Inc.INDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT06451497 | This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 100 | Zumutor Biologics Inc.INDUSTRY | 1 | Apr 2, 2026 | clinicaltrials |
| NCT07247201 | Integrating Allogeneic NK Cells in High-risk Advanced Stage III-IV Nasopharyngeal Cancer Patients(AlloNK1) | not yet recruiting | Phase 1 / Phase 2 | 31 | Singapore General HospitalOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07501650 | Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer | recruiting | Phase 1 | 6 | Thomas Jefferson UniversityOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT02287311 | Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)(MABEL) | active not recruiting | Phase 1 | 38 | Baylor College of MedicineOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07320963 | Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma. | not yet recruiting | Phase 1 / Phase 2 | 52 | Sun Yat-sen UniversityOTHER | 0 | Mar 20, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 11, 2026source: clinicaltrials